Tenaya Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase an aggregate of 12,000 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment. The stock options have an exercise price of $1.97 per share, which is equal to the closing price of Tenaya's common stock on November 15, 2024. Each stock option has a ten-year term and vests as follows over a total of four years: 1/4th of the original number of shares subject to the stock option shall vest on the one-year anniversary of the employee's date of hire and 1/48th of the original number of shares subject to the stock option shall vest every month thereafter, subject to such employee's continued service with Tenaya on each such date.
加利福尼亞州南舊金山，2024年11月19日（GLOBE NEWSWIRE）——Tenaya Therapeutics Inc.（納斯達克股票代碼：TNYA）是一家臨床階段的生物技術公司，其使命是發現、開發和提供解決心臟病根本原因的潛在治療療法。該公司今天宣佈，它向兩名新的非執行員工授予股票期權，購買總共12,000股Tenaya普通股，以供他們開始工作。股票期權的行使價爲每股1.97美元，等於2024年11月15日Tenaya普通股的收盤價。每種股票期權的期限爲十年，歸屬方式如下：股票期權的原始股票數量的四分之一應在員工受聘之日一週年之日歸屬，此後每個月應歸屬於股票期權的原始股份數量的四分之一，前提是該員工在每個此類日期繼續在Tenaya任職。
The stock options are subject to the terms and conditions of the Tenaya Therapeutics Inc. 2024 Inducement Equity Incentive Plan and related forms of agreements, and were granted as an inducement material to each new employee's acceptance of employment with Tenaya in accordance with NASDAQ Listing Rule 5635(c)(4).
股票期權受Tenaya Therapeutics Inc.2024年激勵股權激勵計劃和相關協議的條款和條件的約束，根據納斯達克上市規則5635（c）（4），股票期權是作爲激勵材料授予每位新員工接受在Tenaya工作。
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya employs a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of genetic medicines aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. Tenaya's pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), TN-301, a small molecule HDAC6 inhibitor intended for heart failure with preserved ejection fraction (HFpEF), and multiple early-stage programs in preclinical development. For more information, visit .
關於Tenaya療法
Tenaya Therapeutics是一家處於臨床階段的生物技術公司，致力於實現一項大膽的使命：發現、開發和提供潛在的治療療法，以解決心臟病的潛在驅動因素。Tenaya利用一系列綜合內部能力，包括與模式無關的靶點驗證、衣殼工程和製造，來生成一系列旨在治療罕見遺傳疾病和更常見的心臟病的遺傳藥物組合。Tenaya的產品線包括 TN-201、一種治療mybpc3相關肥厚型心肌病（HCM）的基因療法、TN-401、PKP2相關心律失常的右心室心肌病（ARVC）的基因療法、用於治療心力衰竭的小分子 HDAC6 抑制劑 TN-301，以及多個處於臨床前開發的早期項目。欲了解更多信息，請訪問。
CONTACT: Contact
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
聯繫人：聯繫我們
米歇爾·科拉爾
企業傳播和投資者關係副總裁
IR@tenayathera.com
